Back

Find the FamiCord brand in your country

Free guide

Smart Cells free guide

Download

Transplant stories

Real Treatments. Real Families. Real Hope.

Smart Cells was the first private UK stem cell bank to release samples for transplant — proving that family cord blood banking is not just about storage, but about delivering real therapies when they are needed most.

Why Stem Cell Transplants Matter

At some point in life, your child or family member may need access to stem cell therapy. Today, these treatments are being used for:

  • Blood cancers such as leukaemia and lymphoma
  • Inherited genetic disorders including thalassemia and sickle cell disease
  • Neurological conditions such as cerebral palsy and brain injury
  • Immune deficiencies and metabolic disorders
  • Emerging therapies for sports injuries, inflammatory conditions, and skin repair

By preserving your baby’s umbilical cord blood and tissue, you safeguard access to these life-saving and life-enhancing possibilities.

Proven Track Record

Smart Cells has released more stem cell samples for treatment than any other private UK bank, with a 100% success rate for every sample delivered to clinicians worldwide.

These samples have helped children and families across the globe face illnesses such as:

  • Cerebral Palsy
  • Thalassemia
  • Leukaemia
  • HSV Encephalitis
  • Immune system disorders

Each transplant is more than a statistic — it represents a child given new options, and a family given hope.

A Milestone for Families and for Science

Every successful release shows how far the field of stem cell research has advanced. What was once only a possibility is now a proven therapy.

Yet many parents are still unaware of the benefits of storing their baby’s cord blood and tissue. Smart Cells is working to change that — by raising awareness, sharing real transplant stories, and supporting research into the next generation of regenerative treatments.

Powered by FamiCord: Europe’s Stem Cell Leader in banking and use of cells

As part of the FamiCord Group, Europe’s largest family stem cell bank and one of the world’s top three:

  • Families gain access to 1,000,000+ stored cord blood units across the network
  • Therapies are supported by specialist research centres and clinical teams in 35+ countries including FamiCord Programme for brain disorders
  • FamiCordTx, the group’s advanced therapies division, is actively developing new cell-based treatments to extend the possibilities for families everywhere

Together, Smart Cells and FamiCord stand at the forefront of innovation, offering parents confidence today — and hope for tomorrow.

FamiCord Group releases

Patients

7800+

Expand table
No. Source Source type Diagnosis Medical sector Year of application Therapy Country Age of the recipient
801 Bone Marrow Family Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 77
802 Bone Marrow Family Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy France 23
803 Bone Marrow Family Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Germany 58
804 Bone Marrow Family Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy United Kingdom 53
805 Bone Marrow Family Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Germany 75
806 Bone Marrow Family Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 61
807 Bone Marrow Family Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy France 8
808 Bone Marrow Family Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 63
809 Bone Marrow Family Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Ukraine 38
810 Bone Marrow Family Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Germany 70
811 Bone Marrow Family Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy USA 69
812 Bone Marrow Family Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy France 31
813 Bone Marrow Family Allogeneic Acute Myleogenous Leukemia, alloPBST 7/2025 Hematology 2025 Standard Therapy Germany 53
814 Bone Marrow Allogeneic Aplastic Anemia Hematology 2025 Standard Therapy Spain 15
815 Bone Marrow Allogeneic Severe Aplastic Anemia Hematology 2025 Standard Therapy Norway 55
816 Bone Marrow Allogeneic Inherited Immune System Disorder Hematology 2025 Standard Therapy France 3
817 Bone Marrow Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy USA 7
818 Bone Marrow Allogeneic Severe Aplastic Anemia Hematology 2025 Standard Therapy Ukraine 36
819 Bone Marrow Allogeneic Inherited Immune System Disorder Hematology 2025 Standard Therapy France 10
820 Bone Marrow Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy USA 76
821 Bone Marrow Allogeneic Severe Aplastic Anemia Hematology 2025 Standard Therapy Poland 39
822 Bone Marrow Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy South Africa 6
823 Bone Marrow Allogeneic Wiskott-Aldrich syndrome Hematology 2025 Standard Therapy Turkey 6
824 Bone Marrow Allogeneic Combined immnunodeficiency Hematology 2025 Standard Therapy Ukraine 3 months
825 Bone Marrow Allogeneic Chronic Granulomatous Disease Hematology 2025 Standard Therapy Poland 3
826 Bone Marrow Allogeneic Mixed Phenotype Acute Leukemia Hematology 2025 Standard Therapy Poland 13
827 Bone Marrow Allogeneic Severe Aplastic Anemia Hematology 2025 Standard Therapy Poland 7
828 Bone Marrow Allogeneic B-cell precursor Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Poland 56
829 Bone Marrow Allogeneic Severe Aplastic Anemia Hematology 2025 Standard Therapy Poland 43
830 Bone Marrow Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Poland 19
831 Bone Marrow Allogeneic Very Severe Aplastic Anemia Hematology 2025 Standard Therapy Poland 12
832 Bone Marrow Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Poland 5
833 Bone Marrow Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Poland 10 months
834 Bone Marrow Allogeneic Severe Aplastic Anemia Hematology 2025 Standard Therapy Poland 6
835 Bone Marrow Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 44
836 Bone Marrow Allogeneic Paroxysmal Nocturnal Hemoglobinuria Hematology 2025 Standard Therapy Poland 25
837 Bone Marrow Allogeneic Juvenile Myelomonocytic Leukemia Hematology 2025 Standard Therapy Poland 4
838 Bone Marrow Allogeneic Severe Aplastic Anemia Hematology 2025 Standard Therapy USA 21
839 Bone Marrow Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Italy 12
840 Bone Marrow Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Hungary 10
841 Bone Marrow Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Czechia 68
842 Bone Marrow Allogeneic Adrenoleukodystrophy Hematology 2025 Standard Therapy Poland 53
843 Bone Marrow Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Germany 4
844 Bone Marrow Allogeneic Severe Aplastic Anemia Hematology 2025 Standard Therapy France 4
845 Bone Marrow Allogeneic Paroxysmal Nocturnal Hemoglobinuria Hematology 2025 Standard Therapy Norway 18
846 Bone Marrow Allogeneic Severe Aplastic Anemia Hematology 2025 Standard Therapy Spain 24
847 Bone Marrow Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Belarus 5
848 Bone Marrow Allogeneic Severe Aplastic Anemia Hematology 2025 Standard Therapy Germany 53
849 Bone Marrow Allogeneic diamond-Balckfan anemia Hematology 2025 Standard Therapy Germany 11
850 Bone Marrow Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 57
851 Bone Marrow Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 61
852 Bone Marrow Allogeneic Severe Aplastic Anemia Hematology 2025 Standard Therapy France 3
853 Bone Marrow Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Belarus 1
854 Bone Marrow Allogeneic pB-Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Germany 15
855 Bone Marrow Allogeneic OHID XIAP – Other Histiocytic Disorders / X-Linked Inhibitor of Apoptosis Protein Hematology 2025 Standard Therapy Switzerland 2
856 Bone Marrow Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 46
857 Bone Marrow Allogeneic Acquired Idiopathic Sideroblastic Anemia Hematology 2025 Standard Therapy Russian Federation 5
858 Bone Marrow Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 10
859 Bone Marrow Allogeneic Hodgkin Lymphoma Hematology 2025 Standard Therapy USA 47
860 Bone Marrow Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy CROATIA 11
861 Bone Marrow Allogeneic Juvenile myelomonocytic leukemia Hematology 2025 Standard Therapy Poland 5
862 Bone Marrow Allogeneic Severe Aplastic Anemia Hematology 2025 Standard Therapy Brazil 12
863 Bone Marrow Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Australia 8
864 Bone Marrow Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Italy 3
865 Bone Marrow Allogeneic Myelodysplatic Syndrome Hematology 2025 Standard Therapy USA 60
866 Bone Marrow Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Russia 36
867 Bone Marrow Allogeneic Thalassemia major Hematology 2025 Standard Therapy Turkey 10
868 Bone Marrow Allogeneic Severe Aplastic Anemia Hematology 2025 Standard Therapy Poland 58
869 Bone Marrow Allogeneic Severe Aplastic Anemia Hematology 2025 Standard Therapy Poland 2
870 Bone Marrow Allogeneic Severe Aplastic Anemia Hematology 2025 Standard Therapy USA 18
871 Bone Marrow Allogeneic Other Non-Malignant Disease, Specify Hematology 2025 Standard Therapy USA 17
872 Bone Marrow Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 15
873 Bone Marrow Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Italy 15
874 Bone Marrow Allogeneic aplastic anemia Hematology 2025 Standard Therapy Belgium 36
875 Bone Marrow Allogeneic Primary Refractory Hematology 2025 Standard Therapy Ireland 27
876 Bone Marrow Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 39
877 Bone Marrow Allogeneic Sickle Cell Disease (SCD) Hematology 2025 Standard Therapy Italy 8
878 Bone Marrow Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 68
879 Bone Marrow Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy USA 58
880 Bone Marrow Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 1
881 Bone Marrow Allogeneic Severe Combined Immunodeficiency Hematology 2025 Standard Therapy United Kingdom 13
882 Bone Marrow Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Denmark 38
883 Bone Marrow Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 17
884 Bone Marrow Allogeneic Fanconi Anemia Hematology 2025 Standard Therapy Poland 11
885 Bone Marrow Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 9
886 Bone Marrow Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy USA 3
887 Bone Marrow Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy France 9
888 Bone Marrow Allogeneic Fanconi Anemia  Hematology 2025 Standard Therapy Poland 8
889 Bone Marrow Allogeneic Immune Deficiency Hematology 2025 Standard Therapy United Kingdom 10
890 Bone Marrow Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Germany 12
891 Bone Marrow Allogeneic Severe Aplastic Anemia Hematology 2025 Standard Therapy USA 20
892 Bone Marrow Allogeneic Hodgkin Lymphoma Hematology 2025 Standard Therapy Turkey 17
893 Bone Marrow Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy France 13
894 Bone Marrow Allogeneic Severe Aplastic Anemia Hematology 2025 Standard Therapy Canada 22
895 Bone Marrow Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 15
896 Bone Marrow Allogeneic Severe Aplastic Anemia Hematology 2025 Standard Therapy Italy 8
897 Bone Marrow Allogeneic Inherited Immune System Disorder Hematology 2025 Standard Therapy France 3
898 Bone Marrow Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Italy 2
899 Bone Marrow Allogeneic Bone Marrow Failure Hematology 2025 Standard Therapy Netherlands 23
900 Bone Marrow Allogeneic Chronic Granulomatous Disease Hematology 2025 Standard Therapy Italy 6
Expand table

Stem cell transplantation has become an established procedure

700,000

cord blood collections have been undertaken globally

50,000

hematopoietic stem cell transplants take place every year

400/500

of these transplants are in Europe

Our transplant stories

Smart Cells have released 24 UK
samples to six countries.

Stem cells hold the key to more than 80 life-changing treatments, with clinical trials underway on many more. Replacing damaged cells and tissue, they can even save a child’s life.

Icon

100% infusion success rate

For samples released for transplant.

Icon

3 months – 12 yrs old

Stored cord blood samples have been successfully released for use in transplant for children aged as little as 3 months to 12 years old.

Icon

46% self | 54% siblings

Smart Cells have successfully released stored cord blood samples that have been used for treatment with the child it was collected from and also siblings.

Smart Cells releases

UK samples released

24

Expand table
Sample release date Medical condition Recipient relationship Age of the recipient Unit volume Medical center Country
2005.11 Thalassemia Allogeneic (Sibling) 4 Years 144ml Mount Vernon Hospital Singapore
2005.11 Leukaemia Allogeneic (Sibling) Restricted Restricted Stem Cells and Immunology Department, Birmingham UK
2007.02 Thalassemia Allogeneic (Sibling) 7 Years 76ml Kinderlink der Tu Munchen Germany
2009.08 Cerebral Palsy Autologous (Self) 3 Years 51ml Duke University, North Carolina USA
2010.01 Cerebral Palsy Autologous (Self) 3 Years 81ml Duke University, North Carolina USA
2013.10 Thalassemia Allogeneic (Sibling) 5 Years 58ml Catherine Lewis Centre, Hammersmith UK
2014.01 Leukaemia Allogeneic (Sibling) 4 Years 71ml Medizinische Hochschule, Hanover Germany
2014.05 Cerebral Palsy Autologous (Self) 1 year 68ml Duke University, North Carolina USA
2014.06 HSV Encephalitis & NMDA Receptor Antibody Virus Autologous (Self) 2 Years 57ml Duke University, North Carolina USA
2014.08 Hypoxic Ischemic Encephalopathy (HIE) Autologous (Self) 3 Months 39ml Duke University, North Carolina USA
2015.02 Hypoxic Ischemic Encephalopathy (HIE) Autologous (Self) 6 Months 53ml Duke University, North Carolina USA
2015.03 Severe Combined Immune Deficiency Autologous (Self) 3 Months 74ml Duke University, North Carolina USA
2015.03 Sickle Cell Disease Allogeneic (Sibling) 2 .5 Years 57ml BLK Hospital, New Delhi India
2015.11 Thalassemia Allogeneic (Sibling) 12 Years 87ml Children’s Hospital of Pittsburgh of UPMC USA
2016.03 Cerebral Palsy Allogeneic (Sibling) 6 Years 101ml Duke University, North Carolina USA
2017.04 Lymphoblastic Leukaemia (^1) N/A (Identical twin girls) Restricted 125ml Bambin Gesu Childrens’ Hospital, Rome Italy
2017.06 Cerebral Palsy Autologous (Self) 7 Years 82ml Duke University, North Carolina USA
2017.06 Cerebral Palsy Autologous (Self) 3.4 Years 132ml Duke University, North Carolina USA
2018.03 Autism Autologous (Self) 5.4 Years 73ml Duke University, North Carolina USA
2018.03 Cerebral Palsy Autologous (Self) 3.4 years 132ml Duke University, North Carolina USA
2019.06 Cerebral Palsy Allogeneic (Sibling) 3 Years 104ml Duke University, North Carolina USA
2022.02 Cerebral Palsy Allogeneic (Sibling) 11 Years 185ml Duke University, North Carolina USA
2023.08 Cerebral Palsy Allogeneic (Sibling) 3 Years 46ml Duke University, North Carolina USA
2024.01 Thalassaemia Allogeneic (Sibling) 8 Years 45ml Cincinnati Children’s Hospital Medical Center USA
Expand table
Icon

Ready to get started or need more information?